Debt-to-equity of Cadrenal Therapeutics, Inc. from 30 Sep 2023 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cadrenal Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2023 to 30 Sep 2025.
  • Cadrenal Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 37%, a 77% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Cadrenal Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 37% +16% +77% 30 Sep 2025
Q2 2025 35% +21% +152% 30 Jun 2025
Q1 2025 35% +24% +239% 31 Mar 2025
Q4 2024 30% +21% +222% 31 Dec 2024
Q3 2024 21% -53% -72% 30 Sep 2024
Q2 2024 14% 30 Jun 2024
Q1 2024 10% 31 Mar 2024
Q4 2023 9.3% 31 Dec 2023
Q3 2023 74% 30 Sep 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.